BCL2 and prostate cancer: The resulting CLIFI value distributions indicated heterogeneity in the expression of several proteins (MYH11, ERα, BCL2) across different cancer types (including brain glioma, breast, kidney, thyroid and prostate cancer) aligning with the original raw expression data.